Palvella Therapeutics, Inc.

PVLA

$155.47

+1.65%

2026-09-03 16:00:00 EDT+$2.52

Healthcare

Biotechnology

NASDAQ

Active Trading

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with ...

C-Suite Executives

(0)

The C-suite executives form a cohesive leadership team driving the company's financial strategy and innovation.

Key Team Members

No executives available for this level

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Gender	Year Born	Status
Wesley H. Kaupinen	Founder, President, Chief Executive Officer & Director	USD 935,018		—	Active
Kathleen Goin	Chief Operating Officer	USD 673,820		1971	Active
Matthew E. Korenberg	CFO, Corporate Secretary & Treasurer	USD 665,420		1975	Active
Jeffrey Martini	Chief Scientific Officer	USD 530,435	—	1978	Active
Sarah Foster	Senior Vice President of Human Resources	—		—	Active
Ashley Kline	Chief Commercial Officer	—		1981	Active
Bohan Wei	Vice President of Corporate Development & New Product Planning	—		—	Active
Emily Cook	Senior Vice President of Clinical Operations	—		—	Active
Jason Burdette	SVP of CMC & Technical Operations	—		—	Active
Kent Taylor	Senior Vice President of Sales	—		—	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total
2026-04-30	2025	Wesley H. Kaupinen	President President and Chief Chief Executive Officer	Founder / CEO	$575.00K	$0	$0	$2.47M	$359.38K	$643	$3.40M
2026-04-30	2025	Kathleen Goin	Chief Chief Operating Officer	C-Level	$481.30K	$0	$0	$1.31M	$192.52K	$0	$1.98M
2026-04-30	2025	Matthew E. Korenberg	Chief Chief Financial Officer	C-Level	$475.30K	$0	$0	$1.31M	$190.12K	$0	$1.97M
2026-04-30	2024	Wesley H. Kaupinen	President President and Chief Chief Executive Officer	Founder / CEO	$384.92K	$515.50K	$0	$4.53M	$0	$643	$5.44M
2026-04-30	2024	Kathleen Goin	Chief Chief Operating Officer	C-Level	$381.44K	$257.52K	$0	$485.61K	$0	$0	$1.12M

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

Supply Chain of PVLA

RELATIONS

Upstream

MedPharmLigand Pharmaceuticals IncorporatedNASDAQ:LGNDContract Research Organizations (CROs) - UnnamedRapamycin (Sirolimus) API Manufacturers - UnspecifiedExcipient & Packaging Material Suppliers - Unspecified

Downstream

Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDPC Project (Patient Advocacy Organization)Specialty Pharmacies (Unnamed - Planned)

Proxies

Ligand Pharmaceuticals IncorporatedNASDAQ:LGND Krystal Biotech, Inc.NASDAQ:KRYS Castle Biosciences, Inc.NASDAQ:CSTLPieris Pharmaceuticals, Inc. (Legacy)Unconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer